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Abstract
Since the successful introduction of in vitro fertilization in 1978, medically assisted reproduction (MAR) has
proliferated in multiple clinical innovations. Consequently, egg cells have become an object of demand for both
infertility treatment and stem cell research, and this raises complex legal, ethical, social and economic issues.
In this paper we compare how the procurement and use of human egg cells is regulated in two countries: Israel
and Austria. Israel is known for its scientific leadership, generous public funding, high utilization and liberal
regulation of assisted reproductive technology (ART). Austria lies at the other extreme of the regulatory spectrum
in terms of restrictions on reproductive interventions.
In both countries, however, there is a constant increase in the use of the technology, and recent legal
developments make egg cells more accessible. Also, in both countries the scarcity of egg cells in concert with the
rising demand for donations has led to the emergence of cross-border markets and global ‘reproductive tourism’
practices. In Israel, in particular, a scandal known as the ‘eggs affair’ was followed by regulation that allowed egg
cell donations from outside the country under certain conditions.
Cross-border markets are developed by medical entrepreneurs, driven by global economic gaps, made possible by
trans-national regulatory lacunae and find expression as consumer demand. The transnational practice of egg cell
donations indicates the emergence of a global public health issue, but there is a general lack of medical and
epidemiological data on its efficacy and safety. We conclude that there is need for harmonisation of domestic laws
and formulation of new instruments for international governance.
Introduction
Since the successful introduction of in vitro fertilization
in 1978, medically assisted reproduction (MAR) has pro-
liferated in multiple clinical innovations. Consequently,
egg cells have become an object of demand for both
infertility treatment and stem cell research. However,
the procurement of egg cells involves conflicting inter-
ests and raises multiple concerns and ethical issues. In
this paper we compare the approach to egg cell dona-
tions in two countries with populations of comparable
size (around 8 million): Israel and Austria. First we pro-
vide a general background on the medical practice of
egg cell donations for infertility therapy, the commercia-
lization of reproductive medicine and the concerns
about the commodification of women’s body parts,
given the intrinsic scarcity of egg cells and the growing
demand for egg cells both for reproduction and for
stem cell research. Then we compare ART utilization
rates in Israel and Austria, and the different regulatory
approaches. Finally we focus on the emergence of cross-
border markets in reproductive tourism, in which egg
cells become a coveted commodity, as a result of eco-
nomic gaps and differences in law and policy between
countries. We conclude that there is need for harmoni-
sation of domestic laws and formulation of new instru-
ments for international governance.
Egg cells
Third-party reproduction
Since the birth of the first in vitro fertilisation (IVF)
baby, Louise Brown, in 1978, it is estimated that 3.75
million babies have been born world wide with the
assistance of medical reproductive technologies [1]. In
2010 the Nobel Prize was awarded to the embryologist
Robert Edwards for his pioneering work on IVF, noting
that its development was “a medical advance that
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represents a paradigm shift in the treatment of many
types of infertility” [2]. Indeed, IVF was introduced as a
treatment for female infertility in the case of blocked
fallopian tubes, but by the mid-1990s it had become
standard treatment for male infertility together with
intra-cytoplasmic sperm injection (ICSI)1, as well as for
cases of infertility with unknown cause [1]. IVF is also
utilised with third-party reproduction practices (sperm
donors, surrogate mothers and egg cell donors), primar-
ily to address medical indications of infertility in hetero-
sexual couples, and subsequently to overcome non-
medical obstacles to pregnancy and parenthood, for sin-
gles and same sex couples.
Like in the case of IVF, medical indications for egg
cell2 donation expanded rapidly. At first, it was indicated
as treatment for female infertility due to ovulatory disor-
ders. It soon came to be used also in cases of genetic
and mitochondrial mutations. In the latter decade,
assisted reproductive technology (ART) with egg cells
donation has been utilised increasingly by menopausal
women who can still carry pregnancies. Since egg qual-
ity is the primary barrier to pregnancy in older women
[3], egg cell donations from younger women have come
to be perceived as a means to extend the child-bearing
years of older women in their late forties and fifties. In
the course of these developments, a market has formed
around the need for egg cells, and they have emerged as
a coveted commodity.
Many of these developments have been driven by pri-
vate medical entrepreneurs. A major factor in the rapid
proliferation of assisted reproductive technology (ART)
was its burgeoning in the USA in what has been
described as a ‘Wild West’ of unregulated research,
characterized by an almost instantaneous translation of
experimental procedures into marketed services [4]. In
recent years, the commercialization of reproductive
medicine has become evident also in the emergence of
transnational markets in reproductive tourism, in which
women are both buyers and sellers, including for the
purpose of egg cell ‘donation’.
Who are the donors? Websites boast that they do not
accept all candidates and pride themselves on their con-
nection with university students, which implies that
their potential donors are young, intelligent and of rela-
tively high socio-economic status. Candidates are
screened for medical counter-indications, such as repro-
ductive disorders or genetic disease. They are described
in terms of personality traits, talents and hobbies. Physi-
cal features are also marketed, either to match the looks
of the prospective egg cell recipient, or a eugenic model
of weight, height, hair, eye color and race, according to
the preferences of the recipients [5]. The websites also
recruit the donors. They persuade women by offering
them significant sums of money, and appealing to their
altruism and generosity to help another woman to get
pregnant, experience childbirth and have a child, even if
she cannot bear genetic offspring. At the end of the day,
though, selling egg cells is not a respected occupation.
Norms of anonymity transform the intimacy of repro-
ductive relations into a cold business transaction, create
secrecy, shame and taboo, and make it all too easy to
objectify the egg donor - as if ‘the lady vanishes’ [6].
While there is a degree of market activity around
sperm donation as well, major concerns arise in relation
to the exploitation of women and the commodification
of female body parts. Male and female reproductive fac-
tors are not analogous: sperm is abundant, easily obtain-
able and inexpensive; whereas egg cells are a scarce
resource and their procurement entails risky and inva-
sive intervention in the woman’s body. In the context of
third-party reproduction, the female body and its repro-
ductive parts are of much higher market value than the
male one. Interestingly enough, the need for eggs seems
to be greater than for wombs, and the commerce in egg
cells in recent years seems to have outgrown the surro-
gacy market. In Israel, for example, the number of
requests to approve surrogacy agreements, over a period
of fifteen years, is in the range of several hundreds.3 On
the other hand, during the parliamentary discussions of
the Eggs Donation Law, 2010, estimates of the number
of women seeking egg cell donations each year were in
the thousands. Meanwhile, stem cell research for regen-
erative medicine presents an additional demand for egg
cells that competes with the need for reproductive pur-
poses [7].
Scarcity and delicacy
Human egg cells were not known as such until their dis-
covery by the embryologist Karl Ernst von Baer in 1826.
At the time, they were thought to be a mere vessel for
the male semen, and their essential contribution to
embryo formation was not acknowledged until the sec-
ond half of the 19th century [8]. Today we know the
details of the sophisticated biological processes regulated
by hormones which lead to the formation of mature egg
cells in women of reproductive age. It seems that the
entire pool of immature egg cells is built up prenatally,
peaking at the 20th week of fetal development. After-
wards, a process termed atresia systematically reduces
their amount from 6 to 7 million to about 2 million at
birth, and even further to about 250,000 by the start of
menstruation. During a woman’s reproductive years,
usually one more or less immature egg cell will embed
in the follicle per cycle,4 and only between 300 and 500
egg cells will mature overall to a stage in which they
can be fertilized. This intricately regulated process starts
to wind down around the age of 40 and finally stops
around the age of 50. The ovarian ageing process affects
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both the quantity and quality of egg cells, and this in
turn results in increased rates of chromosomal disorders
making pregnancy impossible in the majority of cases or
causing more or less severe birth defects. Numerous fac-
tors can disturb the complex processes of ovarian func-
tion which may lead to premature ovarian failure and
infertility [9,10].
In other words, the mature egg cell is a precious nat-
ural specimen for each woman. Because in most natural
cycles only a single follicle matures, it has become stan-
dard IVF procedure to administer hormonal treatment
so as to induce artificial maturation of more than one
egg cell, and to stimulate the release of a large number
of eggs in any one menstrual cycle. However, the risks
of intervention for egg cell procurement are substantial.
First, the hormonal treatment regimens can carry
adverse reactions. Ovarian hyper-stimulation syndrome,
a potentially life-threatening condition, is one of the
more prominent immediate risks, while knowledge of
the long-term effects is limited so far. Milder stimula-
tion protocols are less risky and show cumulative preg-
nancy rates that are comparable to standard protocols,
but may require more cycles of treatment [11-13]. In
addition, the egg retrieval procedure itself is intrusive
and requires local or general anesthesia. (See Additional
File 1 for a description of the health risks in Israel’s
standard IVF informed consent form.)
At the same time, commercialized medical practices
are often geared towards maximizing productivity or
optimizing yields, and are driven by ‘competition for
patients, desire for high fertility rates and the need for
quick results’, at the expense of donor health [13].
Because many of these practices take place in the private
market, there is inadequate epidemiological data on the
risks for egg donors, but anecdotal testimonies indicate
that they can be substantial [14]. One UK press report
brought the stories of two women who claimed to have
suffered health damage after donating eggs at a clinic in
Bucharest which was collaborating with a private clinic
in London. One of the women, aged 18 at the time of
the donation, was left with scarred ovaries that rendered
her infertile [15].
Stem cell research
Meanwhile, egg cells have also become a coveted com-
modity in embryonic stem cell research for the purpose
of personalised regenerative medicine (i.e., the potential
production of homologous tissue or organs for trans-
plantation in sick persons). Any progress in this area
will translate rapidly into economic profit long before it
reaches the patient’s bedside, and this creates a conflict
of interest that can compromise research integrity.
This came to light in 2005, in what came to be known
as the Korean stem cell scandal. The affair involved a
veterinarian scientist who had published two papers in
Science magazine in which he claimed to have success-
fully extracted stem cells from human embryos cloned
by means of somatic cell nuclear transfer (SCNT).5 Alle-
gations of scientific misconduct were exposed by jour-
nalists and led to an independent investigation
conducted by Seoul National University, which found
that the scientist had intentionally fabricated research
results. Consequently Science retracted the fraudulent
publications. The investigation also found ethical mis-
conduct in the appropriation of the human egg cells
that were used for the cloning research. The scientist
claimed to have used a new technique that reduced the
need for eggs. However, contrary to his claim of having
used 185 eggs, according to research records kept in his
laboratory at least 273 eggs were shown to have been
used [16]. Korea’s National Bioethics Board found that
he had used a total of 2,221 eggs from 119 women, and
there were serious shortcomings in the process of
obtaining informed consent from them [17]. Among
other things, the research team did not properly inform
women about the health risks involved in the follicle sti-
mulation protocols and the egg cell procurement proce-
dure, junior members of the research team were
pressured into providing egg cells, and researchers had
paid donors although the consent form stated that they
had received no financial payment [7,18].
Following this scandal SCNT research fell into some
disrepute, while scientists’ interest shifted to a certain
degree from embryonic to adult stem cells. Alternative
methods have been established to achieve induced pluri-
potent cell lines6 from adult skin cells, without using
egg cells or embryos, and research in this field is pro-
gressing rapidly [19]. Nonetheless, the SCNT approach
is still a subject of strong research interest [20]; and egg
cells remain an important raw material for research in
reproductive and regenerative medicine. There is also
interest in parthenogenic blastocysts7 for use in poten-
tial cell therapies. Patient-specific transplantation tissues
and organs or ‘personalised’ stem cell therapies, with
either SCNT embryos or parthenogenic blastocysts,
would require large numbers of egg cells for translation
into clinical practice. If such research proves to have
clinical application, the availability of sufficient numbers
of egg cells will become a major problem and is likely to
exceed the demand generated by infertility treatments
[21].
Another experimental technique that is intended to
‘repair’ egg cells of IVF patients illustrates both the reci-
procal impetus of reproductive and regenerative medi-
cine and the rapid translation of experimental
procedures into clinical practice. In analogy to SCNT,
chromosomes from a patient’s egg cell can be intro-
duced into an enucleated healthy donor egg cell in
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order to avoid transmission of defects connected to
mutations of mitochondrial DNA.8 Recently, the UK
Human Fertilisation and Embryology Authority pub-
lished a report on the technique, referred to as ‘three-
parent IVF’ because the offspring would have a small
amount of the egg donor’s genetic material and there-
fore three genetic parents [22]. Although further
research is needed, researchers are already pressing the
government to prepare legislation that would make the
procedure legal for translation into clinical practice [23].
Israel and Austria
ART utilization
In both Israel and Austria the first IVF birth was reported
in 1982, and subsequently ART services have become the
standard of care. 24 IVF centers have been operating since
2002 in Israel [24], whereas in Austria, there were 25 oper-
ating clinics in 2006 [25], and 27 in 2009 [26]. There is no
available official data specifically on egg cell donations or
implantations. However, differences in utilization rates
and the extent of public funding for ART in general can
be seen from the following data.
Israel is known for its high rates of ART utilization
and innovative clinical practices. It boasts by far the
highest rates of intervention in the world, measured by
the number of IVF treatment cycles per capita [27,28].
In Austria, reproductive interventions are far less accep-
table, and ART utilization rates are lower:
• In 2002, the total number of IVF cycles in Austria
was 4,680 (including ICSI and frozen embryo trans-
fer)[29] compared with 20,886 in Israel [24].
• In Austria, for 2004, 658 live births following ART
were reported [27], whereas for the same year in
Israel, Ministry of Health (MoH) data indicated
3,574 live births9 [24].
• In Austria, ART live births accounted for about
1.3% of all births in 2008 [26], compared with 3% in
Israel [24].
Austria and Israel also differ in the scope of public
funding. In Austria, in 2008, 289 of the 1,039 ART live
births were in public clinics while 750, the majority,
were in private clinics [26]. Under Austria’s IVF Fund
Act, 1999 (IVF-Fonds-Gesetz) subsidies cover 70% of
treatment costs for a maximum of four cycles in eligible
clinics (both public and private), with a possibility of
additional cycles of treatment if pregnancy was achieved
within the first four [30]. In Israel, funding under the
National Health Insurance (NHI) Law, 1995 covers
unlimited IVF treatment cycles for up to two children
within the current relationship.
Austrian law does not allow egg cell donation, as we
shall see, but in Israel, clinical guidelines for public
funding of IVF, issued in 1998, recommended that
women undergoing IVF with their own eggs would be
eligible for public funding only up to the age of 45
years, while the age limit for women undergoing IVF
with donor eggs was set at 51 [31]. The Eggs Donation
Law, 2010 extended the age of eligibility for accessing
treatment by another three years, to 54. It is yet to be
seen whether public funding guidelines will be adjusted,
or whether the gap between the Law and the guidelines
will create a new market for private medical practice.
There are multiple cultural factors that explain the dif-
ferences in the use and public funding of ART in Israel
and Austria. Israeli doctors are leaders in ART research
and development. Jewish tradition places high value on
the religious commandment to be fruitful and multiply,
and the family is a central institution in social life. Israeli
individuals and society have a general propensity to accept
and consume technological novelties. Demographic policy
is pro-natal against the historic backdrop of the Holocaust
and in the context of the Israeli-Palestinian conflict
[32-34]. And the Supreme Court has struck down restric-
tions on access to ART under Israel’s IVF regulations [35]
on more than one occasion, on grounds of a constitutional
right to parenthood [36,37].
On the other hand, Austria has a Catholic tradition
that views the fertilised egg as a human being deserving
protection. Like in other western European countries,
fertility rates are below replacement level and women
have the freedom to choose not to have children. In
general, Austrian society is cautious about scientific pro-
gress and due to the history of the Nazi eugenics, the
political culture is sensitive to technical interventions at
the beginning of life. According to a 2010 survey, it is
the least optimistic among European countries about
biotechnology [38]. In addition, Austria’s medical system
is still predominantly public, and the influence of private
biomedicine and the biotechnological industry is small
compared to other western countries. These factors
combine to explain that there is less interest in and
demand for ART in Austria compared with Israel.
At the same time, in both Israel and Austria, there has
been a steady increase in ART utilization rates over the
past decade (Table 1). In Israel, the total number of
treatment cycles rose by 56%, from 2001 to 2009,
Table 1 Increase in ART utilization over the past decade
Israel Austria
year no. of cycles per capita ratio no. of cycles per capita ratio
2001 20,512 12.9 4,726 2.37
2009 31,978 17.8 6,599 3.22
Data for Israel are found in ref. 24; data for Austria were taken from ref. 26.
The per capita ratio is the number of treatment cycles per 1,000 women
between the ages of 15 and 49. Counts of Austrian women of the respective
age group are found on www.statistik.at.
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together with an increase in the per capita ratio10 by
38% [24]. Over the same period of time, in Austria,
there were similar increases. Treatment cycles rose by
39%, and the per capita ratio increased by 36% [26].
These data correspond to observations from other coun-
tries in Europe [25].
Regulation of egg cell donation
(a) Israel
Prior to the enactment of Israel’s Eggs Donation Law,
2010 [39], the IVF Regulations allowed egg cell dona-
tions only by women who were undergoing IVF as infer-
tility treatment. The rationale was that the health risks
could not be justified unless the intervention was under-
gone primarily for the donor’s own benefit. But given
the difficulty in obtaining human egg cells, infertility
patients ordinarily prefer to fertilize and preserve for
their own use all the eggs retrieved in a given cycle. The
discrepancy between the reluctance of patients to donate
eggs and the increasing demand for donations led to a
so-called ‘shortage’. Private clinics started offering eco-
nomic inducements to infertility patients to donate eggs,
by waiving certain costs of treatment if they would
agree to ‘share’ their eggs with others [40]. However,
this source dried up for all practical purposes after the
exposure, in 2000, of a scandal that came to be known
as the ‘eggs affair’.
The affair came to light when some women filed a
personal injury action claiming damages from one of
Israel’s leading fertility experts, who was a chief of gyne-
cology at one of its largest public hospitals. The plain-
tiffs alleged that the doctor submitted them to excessive
hormonal stimulation, retrieved dozens of eggs from
single treatment cycles, and used these eggs in the treat-
ment of large numbers of recipients at a private clinic -
without their informed consent. The case was eventually
settled out of court, but the plaintiffs had also com-
plained to the police, and this led to a criminal investi-
gation [41]. The criminal proceedings culminated in a
plea bargain, according to which the doctor confessed to
certain facts and the matter was referred to a profes-
sional disciplinary tribunal, which eventually suspended
his medical license for a period of two and a half years.
Because the case was not adjudicated in a court of law,
and the decisions of the disciplinary court are not made
public, the full facts of the affair were never made clear.
According to journalist reports, the doctor confessed
that in one case he removed 232 ova from one patient
and used 155 of them for 33 recipients, and in another,
he took 256 ova and used 181 for treating 34 other
women [42].
A crisis of trust between infertility patients and their
doctors resulted, and the practice of eggs donation in
Israel ceased almost entirely. At the time, it was
estimated that 2,000 women in Israel were waiting for a
donation [43]. The MoH responded by appointing an ad
hoc committee which concluded its deliberations in
2001 and recommended legislation to allow donations
by healthy volunteers [44], but it took almost ten more
years until the Eggs Donation Law was enacted in 2010.
Meanwhile, the practical solution to the local shortage
was to allow (or create) a cross-border flow of human
egg cells from other countries in which there were no
legal restrictions on young healthy woman acting as
donors, or on paying them to do so. Thus, the MoH
amended the IVF Regulations so as to permit the use of
egg cells imported from other countries [45]. Nonethe-
less the numbers of women in need continued to grow.
By 2007, when the legislature took up the governmental
initiative to enact a law that would allow donation by
healthy volunteers inside Israel, the numbers of women
waiting for egg donations was estimated at 6,000 by a
patient organization advocate [46], a three-fold increase
since the start of the public debate in 2000.
In addition there was a new demand of scientists for
egg cells for the purpose of cloned stem cell research.
While Israel’s anti-cloning statute prohibits reproductive
cloning [47], stem cell research with embryos cloned
from human egg cells is not forbidden, subject to
approval by an ethics review committee. However,
under the IVF Regulations, egg cells taken from a
woman’s body could be used only for the purpose of
reproduction, and this precluded their use for research.
Consequently, in 2003, the committee vested with advi-
sory authority under the anti-cloning statute called for a
change in legal regulation that would allow the donation
of egg cells for research [48]. In view of this, the MoH
put on hold the draft legislation proposed in 2001, to
allow egg cell donations by healthy volunteers for infer-
tility treatment, so as to prepare a comprehensive legis-
lative proposal that would include donations for
research as well. The bill was published in 2007 [49]
and eventually enacted by the Knesset in 2010.
The essence of the Eggs Donation Law, 2010 is to
allow donations from healthy volunteers, primarily for
infertility treatment, but the donor may designate up to
2 egg cells (or 20% of the total number of those
retrieved in any given cycle) either for research or to be
frozen for her own future use. In this respect the Law is
permissive, but at the same time it subjects the practice
of egg cell donation to detailed regulation. The donor
must be between 21 and 35 years old, and she may
undergo no more than three retrieval cycles, spaced at
intervals of at least 180 days. There can be no more
than two recipients from each retrieval procedure, so
that all in all no more than six children can be born
from any one donor. As mentioned above, there is an
upper limit on the age of the recipient - no more than
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54 years of age. The Law clarifies that the offspring is
the legal child of the recipient and that the donor has
no parental rights or responsibilities. While trading in
egg cells is prohibited (section 8), the state will pay
donors ‘compensation’ in an amount that is to be deter-
mined by the Minister of Health (section 43).
Furthermore, the Law imposes restrictions on the free-
dom of individual donors and recipients and subjects
them to various technocratic mechanisms that are intru-
sive of privacy. For example, a donor may not be a mar-
ried woman; she may not be related to the recipient;
and the donation will be anonymous (section 13), unless
special permission is obtained from an ‘exceptions com-
mittee’ (section 22). Both the recipient and the donor
must submit a formal request - to a ‘responsible physi-
cian’ or the ‘approvals committee’, respectively (sections
11,12). The Law also establishes a ‘data base’ to keep
track of the number of donations from each woman and
to rule out any biological relation between the donor
and the recipient (section 30), as well as an ‘infants reg-
istry’, mainly in order to preclude half-sibling marriage
(section 33);11 but neither the adults involved in the
reproductive collaboration nor the children born as a
result have a right to receive any identifying information
from these sources.
(b) Austria
The law in Austria on MAR has been characterised as
‘restrictive if not hostile’ [50]. The Act on Reproductive
Medicine (Fortpflanzungsmedizingesetz), 1992 [51]
allows the use of ART only within marriage or a stable
heterosexual civil partnership12, and prohibits egg cell
donation. Sperm donation can be used only by couples
where the male partner is infertile, but not in combina-
tion with IVF, and is not available at all to single
women or lesbian couples. In other words, IVF in Aus-
tria may be used only by a married or cohabiting het-
erosexual couple with their own gametes. Women must
be no older than 40, and men - 50, when starting the
treatment. The Act also provides that the mother of any
offspring from IVF is the woman who carried the preg-
nancy, which excludes surrogate motherhood arrange-
ments. Recent discussion of egg cell donation by
Austria’s Bioethics Commission revealed controversy
over issues related to the commodification of egg cells
and the exploitation of donors [52].
Austria is also regarded as one of the countries with
the most restrictive laws on embryo research in Europe
[53]. The Act on Reproductive Medicine states that
human embryo cells capable of development may be
used only for reproduction, and prohibits the creation of
human embryos for research purposes as well as the
procurement of stem cells from ‘surplus’ IVF embryos
(i.e., embryos that will no longer be used by their par-
ents and would otherwise be discarded) [54]. Therefore,
research on embryonic stem cells is not well established
in Austria. At the same time, the Act does not expressly
prohibit the import and use of embryonic cell lines,
Austrian scientists are participating in EU funded pro-
jects of embryonic stem cell research [52,55], and fund-
ing through the Austrian Science Fund is not restricted
for this research field as a matter of principle. There is
currently a discussion as to whether ‘surplus’ embryos
from IVF can be used for research with the informed
consent of the parents. Embryos created by means of
SCNT or parthenogenesis could also be used to estab-
lish stem cell lines, at least in theory, as these embryos
would not have the potential to develop into a child
[52]. Nonetheless, there is no demand in Austria for egg
cells for research, and their use for purposes other than
fertilization raises ethical reservations.
In 1998 two married couples living in Austria and suf-
fering from infertility challenged the constitutionality of
the Act on Reproductive Medicine in a petition to its
Constitutional Court, arguing that the prohibition of
IVF with donated sperm or egg cells infringed the basic
rights to privacy and to found a family guaranteed by
the European Convention on Human Rights [56]. For
the purposes of this paper we focus on egg cells. In
1999, the Court gave its decision, finding that the Act
did interfere with the applicants’ rights, but that the
interference was justified in view of the moral and ethi-
cal implications and the best interests of the child-to-be
[50]. Subsequently, in 2000, the couples applied to the
European Court of Human Rights, which delivered its
decision, in SH v Austria, in 2010 [57].
Austria argued that even though the right to respect
for private life encompasses the right to fulfil the wish
for a child, it does not follow that the State is under an
obligation to permit indiscriminately all technically feasi-
ble means of reproduction. Austria’s legislation was
designed to avoid the forming of ‘unusual’ personal rela-
tions such as a child having more than one biological
mother (a genetic one and one carrying the child). A
third party submission by Germany argued that ‘split
motherhood’ was an absolute novelty in nature and the
history of mankind, and it posed a serious threat to the
welfare of the child. German law also prohibits egg cell
donation [58], and the intention is to protect the child’s
welfare by ensuring the unambiguous identity of the
mother. The child would have difficulty coping with the
fact that two women had a part in his or her biological
existence. This ambiguity might jeopardize the develop-
ment of the child’s personality and self-identity. Another
danger was that of conflict between the two mothers, to
the detriment of the child.
Austria argued further that the aim of its law was to
prevent ‘exploitation and humiliation of women, espe-
cially those from economically disadvantaged
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backgrounds’, who might be pressured to donate egg
cells to other infertile women so as to receive IVF treat-
ment which they could not afford otherwise.13 It was
also concerned about the risks of commercialization and
the use of gamete donation for the ‘selection’ of chil-
dren. Additionally, children had a legitimate interest in
information about their descent, while with donated egg
cells, the actual parentage of a child would not be
revealed in the register of births.
The European Court noted that the state parties to
the European Convention on Human Rights enjoyed a
wide margin to regulate ART in view of the sensitive
moral issues raised with the fast-moving medical devel-
opments related to IVF. Within this margin of discretion
a state may prohibit ART altogether, but once it permits
some of the technological applications it must conform
with the principle of equality. Moral considerations or
concerns about social acceptability were not sufficient
justification to ban a specific technique such as egg cell
donation. The risks, including that of the exploitation of
women, could be minimized by less restrictive safe-
guards, such as the prohibition of remuneration for
donation. The Court acknowledged that the certainty of
motherhood - mater semper certa est - was a basic prin-
ciple of civil law, but noted that family relations which
do not follow the typical biological parent-child relation-
ship, such as adoption, are not new. As for the legiti-
mate interest of individuals to know their actual
parentage, this was not an absolute right and could be
balanced with the competing interest of donors in anon-
ymity. The Court concluded, by a majority opinion, that
it could not justify the difference in treatment between
couples who needed egg cell donation and those who
did not.14
Cross-border egg cell donations
Despite the differences between Israel and Austria with
regard to the law, policy and practice of ART, limited
local access to egg cells in both countries has led to the
emergence of cross-border markets. Israel has been
actively involved in ‘reproductive tourism’ related to egg
cell donations. In Austria, the issue is less visible, but
women there also use cross-border services, and private
fertility clinics offer egg cell donation to their clients in
cooperation with partner clinics in other European
countries, e.g. Spain and the Czech Republic. These
practices are part of a flourishing global market for egg
cells, where transnational IVF clinics broker sales
between generally poor, female vendors and wealthy
purchasers, beyond the borders of national regulation
and with little clinical or bioethical scrutiny [7].
Like other medical tourism practices that lie on a
spectrum between life style spas and cosmetic services,
trafficking in organs for transplantation and the
fraudulent marketing of unproven stem cell treatments
[59], transnational egg cell donations - and surrogacy
too - are driven by differences in law and policy
between countries and economic gaps [55,60]. For
example, ‘pregnancy contracts’ are being outsourced to
India where private fertility clinics are offering surrogate
mother services as part of a $ 2.3 billion medical tour-
ism ‘industry’ because of the low costs and lack of pro-
tective regulation [61,62]. IVF procedures in the
unregulated Indian clinics generally cost a fraction of
what they would in Europe or the U.S., with surrogacy
as little as one-tenth the price [63].
A recent study of six European countries estimated
that between 11,000 to 14,000 patients per year were
seeking cross-border ART services for between 24,000-
30,000 treatment cycles, because of legal restrictions in
the country of origin. For example, single and lesbian
women from France, Norway and Sweden go abroad for
sperm donation, because it is not legally accessible to
them in their home countries. Women from Germany
seek egg cell donations abroad because they are illegal
in their home country. Women from England also travel
abroad for egg cell donations - because of waiting lists
[55]. Differences in economies and payments to egg cell
donors also drive this reproductive tourism. In the USA
payment to donors in the sum of 5,000 USD is standard
[64], while sums of 900 Euro in Spain or 500 Euro in
the Czech Republic have been reported [65], and
women at an Israeli clinic in Romania earned as little as
200 USD per retrieval cycle [66].
The record of Israel’s involvement in extra-territorial
egg cell donation practices is illustrative of the modus
operandi of the global market. As mentioned above, fol-
lowing the cessation of donations by infertility patients
in the wake of the ‘eggs affair’, the IVF Regulations were
amended so as to permit the use of imported egg cells.
The amendment allowed doctors “to implant an egg
retrieved and fertilized outside Israel, in the body of a
woman in Israel” [45]. This meant that the egg cells
would be provided by women at a facility outside Israel:
the sperm of the male partner could be frozen in Israel
and transported to the facility abroad; there the donated
egg cells would be fertilized with the sperm; and the fer-
tilized egg could then be frozen and transported back to
Israel for implantation in the female partner. The MoH
also authorized four clinics in Israel to engage in these
procedures after examining and approving the clinical
conditions and laboratory methods of their collaborating
clinics in Romania and the Ukraine [67].
However, success rates of treatment with frozen
embryos are lower than with freshly fertilized eggs.
Much as medical tourism for kidney donations increased
when it became known that transplantation success
rates were higher with organs from live donors rather
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than from cadavers, so too the evidence-based benefits
of egg cell donation technology gave rise to medical
entrepreneurism in the cross-border market. Israeli doc-
tors started advising their female patients to travel
abroad to collaborating clinics where they would be
implanted with freshly fertilized donated eggs. Some-
times the same doctors set up the IVF facility abroad as
a private enterprise that would service their Israeli
patients as well as those of the local population who
could afford the fees. Often doctors would accompany
their patients and perform the treatment at the clinic
abroad. The website of one prominent private IVF cen-
ter explained the package deal: a woman who wished to
have an egg donation would need to travel abroad for
implantation of the embryos, to the clinic where the egg
cells were donated and fertilized; the flight there and
back would be together with other patients and accom-
panied by a doctor from the center who would also per-
form the implantation. “All air travel arrangements,
plane tickets, taxes, transfers and full pension hotel
accommodation are taken care of by center staff and
included in the cost of treatment” [68]. The cost to
patients was in the range of several thousand Euro or
USD [66,69].
When Israel allowed the use of egg cells from abroad
because its own women were refusing to donate, it
applied a double standard and turned a blind eye
towards dubious practices that occur outside its territory
in less regulated countries. Moreover, the blurring of
medicine as professional practice and business creates a
conflict of interests: between doctors’ fiduciary relation-
ship with the patient and their ethical duties of benefi-
cence and non-maleficence, on the one hand, and their
economic interest in profiting from the business, on the
other. The ethical compromise is expressed in the testi-
mony of a spokeswoman for an egg donation web
forum during the parliamentary debate around the Eggs
Donation Law. She testified that she was going for an
egg donation in Eastern Europe for the tenth time. “It’s
not pleasant to say so”, she said, “but there is good live-
lihood for lots of good and respectable doctors.” ([43],
per Anonymous)
Clinics in public hospitals found that in order to keep
their patients, they had to compete with these private
medical practices, and also set up IVF facilities, mainly
in Eastern Europe. Indeed, in July 2009, yet another
‘eggs affair’ shook Israel, this time with a police raid of
an IVF clinic in Romania, and the detention for ques-
tioning of doctors, patients and management staff under
suspicion of involvement in human egg and stem cells
trafficking. Two of the doctors were employees of a gov-
ernment-owned hospital in Israel, and bedding from
that hospital was being used in the Romanian clinic.
Three years earlier, a MoH official had written a letter
of warning that the clinic was no longer operating with
a license from the Romanian authorities [70-72].
These patterns are typical of reproductive tourism in
general and not unique to Israel, but Israel stands out in
its designation of public funds to support these prac-
tices. In 2005, the MoH issued a circular to clarify that
the health funds were obliged to provide egg cell dona-
tion services outside Israel within the coverage of the
NHI [73]. It was not entirely clear whether the adminis-
trative directive applied only to cases in which the ferti-
lized egg was imported for implantation in Israel, in
accordance with the IVF Regulations, or whether it also
obligated the health funds to cover the costs when the
woman travelled for implantation abroad. In any event,
health funds may provide universal services above and
beyond their legal obligations under the NHI Law, and
it seems that prior to the Romanian scandal they partici-
pated in the costs of donation abroad whatever the cir-
cumstances. In 2008, according to a patient rights
organization website, “because there are no egg dona-
tions in Israel” all the health funds participated in the
costs to the sum of approximately $2,000 [74]. At least
one of the health fund supplementary insurance pro-
grams covered most of the expenditure for up to two
egg donations outside Israel, including when the implan-
tation was performed there [75]. Israel’s generosity in
funding infertility treatments has been criticized as
excessive, because it encourages women to undergo
unlimited cycles of IVF treatment with the attendant
health risks, and because of questions as to funding
priorities in relation to other pressing public health
needs. When cross-border IVF is practiced, however,
the question of public funding gains an additional moral
dimension.
Conclusion
Egg cells are a precious human tissue, due to their scar-
city, biological complexity and economic value. They
can be procured only by means of sophisticated ART
that is intrusive, invasive and risky for the women who
are involved. Therefore the use of egg cells for both
infertility treatment and stem cell research is wrought
with ethical conundrums. This paper has described the
dramatic developments that unfolded around the subject
in Israel and Austria. The two countries represent
extremes on the spectrum of the ethical debate around
the acceptability of egg cell donations. They differ in uti-
lization rates, public funding policies and legal regula-
tion of ART, but in both there has been a steady
increase in domestic usage and the emergence of cross-
border markets developed by medical entrepreneurs, dri-
ven by global economic gaps, made possible by trans-
national regulatory lacunae and finding expression as
consumer demand.
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The need of post-menopausal women for egg dona-
tions appears to be a major factor in the growth of
cross-border markets in latter years. The market mental-
ity is not really appropriate for the collaborations that
are necessary in order to bring a child into the world.
Yet some medical entrepreneurs involved in the busi-
ness of egg cells appear to view women’s bodies as a
natural resource to be mined for profit. It is not surpris-
ing that egg cells are not readily available, and there is a
so-called ‘shortage’. It is an artificial shortage created by
the technological possibility and the demand of ‘consu-
mers’. This demand arises within a complex cultural
context, in which the technological possibilities generate
new social constructs of infertility and hence, new forms
of suffering from childlessness. On the one hand,
women are appropriating the technology so as to experi-
ence pregnancy and childbirth even though they cannot
be genetic mothers. On the other hand, the satisfaction
of their desire comes at substantial cost. The transna-
tional market in egg cells for infertility treatment and
research raises a multitude of ethical issues related to
the commercialization of medicine, the commodification
of human body parts, and the exploitation of women.
Other issues of paramount concern relate to the rights
of the children, such as the right to know their genetic
origins, and the right to naturalization and to enter the
country of the commissioning parent’s origin.
The proliferation of ART, in general, and its use with
egg cell donations, in particular, has been driven by a
rapid translation of medical experimentation into mar-
keted services. In other words, egg cells were ‘harvested’
on a wide scale before the science and technology were
optimized. No doubt there have been benefits. Nonethe-
less, concerns about the long term effects on the health
of children and women in various contexts of IVF are
only now coming to light. There is by now ample evi-
dence that these risks are considerable and that there is
a problem of under-reporting adverse effects. For exam-
ple, the possible immune reaction of a recipient towards
embryos from donated egg cells has been completely
ignored, but recent studies show that serious hyperten-
sive disorders (pre-eclampsia) - a classical case of mal-
adaptation of the mother’s immune system to the fetus -
occur with increased incidence in IVF using donated egg
cells [76,77].
Since much of the practice of egg cell donations takes
place in the private market, there is a general lack of
medical and epidemiological data on its efficacy and
safety. If that lack is to be filled, there is need for har-
monisation of domestic laws and formulation of new
instruments for international governance that will
require transparency and accountability from profes-
sionals. Israel and Austria have very different approaches
of law and policy to egg cell donation but cross-border
issues are common to both, and it is clear that the glo-
bal ventures of medical entrepreneurs pose new chal-
lenges for transnational governance. This paper
indicates the scope of the matter and the need for a
broad and concerted global response. An argument
could be made for extra-territorial criminal jurisdiction.
At the very least, a state ought not to support cross-bor-
der IVF practices with public funds unless it assumes
responsibility to take appropriate measures that will
ensure they do not lead to abuse.
Endnotes
1 ICSI entails the isolation of one sperm cell from the
semen and injecting it directly into the woman’s ova.
2 In this paper we use the term ‘egg cell’ to replace the
interchangeable terms of ‘egg’, ‘oocyte’ or ‘ovum’.
3 The numbers are based on the records of the statu-
tory approvals committee under the Surrogate Mother
Agreements (Approval of the Agreement and Status of
the Child) Law, 1996 since the law came into force, and
were presented by Etti Samama, a researcher from Ben
Gurion University, at a conference held in Tel Aviv on
December 27, 2010.
4 Note that follicular development, which is a neces-
sary support mechanism for egg cell maturation, is itself
a complex and not fully understood biological process.
5 Somatic cell nuclear transfer (SCNT) is a cloning
technique for producing a genetically identical duplicate
of an organism by replacing the nucleus of an unferti-
lized egg cell with the nucleus of an adult cell and then
stimulating it to develop. Cloning for reproductive pur-
poses is forbidden under Israeli law and in many other
countries. So-called therapeutic cloning - i.e., stem cell
research with cloned embryos for potential use in trans-
plantation medicine - would eliminate problems related
to host immune rejection of the grafted tissue.
6 Pluripotency refers to the potential of a stem cell to
differentiate into any type of fetal or adult cell. Induced
pluripotent stem cells, commonly abbreviated as iPSCs,
are adult cells that have been reprogrammed so that
they revert to an embryonic-like state and regain differ-
entiability. Tissues derived from iPSCs would be a nearly
identical match to the cell donor and thus probably
avoid rejection by the immune system, like cloned stem
cells. Hence the hope of researchers that they will prove
useful in personalised regenerative medicine provided
that general drawbacks of pluripotent cells, like tumori-
genicity, can be overcome.
7 Parthenogenesis is asexual production, where the
development of an embryo from an egg cell occurs
without fertilization by a male. Blastocyst refers to the
stage of development when the egg cell has become a
cluster of embryonic cells that is ready to implant in the
lining of the womb. Parthenogenic blasotcysts can be
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generated from mature egg cells by stimulation in vitro.
In humans they will not develop into viable embryos.
8 Each cell contains a general genome in its nucleus
(nuclear DNA) and an extra genome in its mitochon-
dria, the vesicles of cells responsible for energy genera-
tion through respiration. A variety of diseases is
connected to mutations in mitochondrial DNA and
could thus be avoided.
9 The number is calculated as follows: 23,828 cycles ×
15% live births per cycle = 3,574 live births.
10 Treatment cycles per 1,000 women between the
ages of 15 and 49.
11 Concerns about unwitting half-sibling marriage are
universal. In Israel these concerns are raised primarily
by rabbinical authorities because the law of marriage is
predominantly governed by halakha for the Jewish
majority in the country. There is controversy amongst
halakhic authorities as to the marital eligibility of chil-
dren born of third-party reproduction, due to doubts
about mamzerut. This lies beyond the scope of this
paper.
12 Civil partnership is possible in Austria since 2010.
13 The assumption is that the donor will herself be in
need of treatment, as was the case in Israel before the
enactment of its new law.
14 Austria’s appeal against this ruling is pending before
the European Court’s Grand Chamber. On February 23,
2011, the Chamber decided to examine the merits of
the claim of violation of privacy, but rejected the argu-
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